These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21775166)

  • 81. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Clinical and biochemical predictors of increased carotid intima-media thickness in overweight and obese adolescents with type 2 diabetes.
    Kotb NA; Gaber R; Salama M; Nagy HM; Elhendy A
    Diab Vasc Dis Res; 2012 Jan; 9(1):35-41. PubMed ID: 21985955
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Effect of Intensive Blood Pressure Lowering on Left Ventricular Hypertrophy in Patients With Diabetes Mellitus: Action to Control Cardiovascular Risk in Diabetes Blood Pressure Trial.
    Soliman EZ; Byington RP; Bigger JT; Evans G; Okin PM; Goff DC; Chen H
    Hypertension; 2015 Dec; 66(6):1123-9. PubMed ID: 26459421
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
    Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
    Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
    [TBL] [Abstract][Full Text] [Related]  

  • 85. On-treatment C-reactive protein and HDL cholesterol levels in patients at intermediate cardiovascular risk: impact on carotid intima-media thickness.
    Pirro M; Vaudo G; Lupattelli G; Pasqualini L; Mannarino MR; Schillaci G; Alaeddin A; Paciullo F; Fallarino F; Bagaglia F; Mannarino E
    Life Sci; 2013 Sep; 93(8):338-43. PubMed ID: 23871987
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Glycaemic, blood pressure and lipid goal attainment and chronic kidney disease stage of type 2 diabetic patients treated in primary care practices.
    Corcillo A; Pivin E; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2017; 147():w14459. PubMed ID: 28695552
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Diabetic dyslipidemia.
    Kreisberg RA
    Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes.
    Mottl AK; Buse JB; Ismail-Beigi F; Sigal RJ; Pedley CF; Papademetriou V; Simmons DL; Katz L; Mychaleckyj JC; Craven TE
    Clin J Am Soc Nephrol; 2018 Nov; 13(11):1693-1702. PubMed ID: 30361335
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus.
    Hayashi Y; Okumura K; Matsui H; Imamura A; Miura M; Takahashi R; Murakami R; Ogawa Y; Numaguchi Y; Murohara T
    Metabolism; 2007 May; 56(5):608-13. PubMed ID: 17445534
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON.
    Lorenzatti AJ; Monsalvo ML; López JAG; Wang H; Rosenson RS
    Cardiovasc Diabetol; 2021 Apr; 20(1):94. PubMed ID: 33941192
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Lipid lowering therapy in type 2 diabetes.
    Föger B
    Wien Med Wochenschr; 2011 Jun; 161(11-12):289-96. PubMed ID: 21769710
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Impact of a multifactorial treatment programme on clinical outcomes and cardiovascular risk estimates: a retrospective cohort study from a specialised diabetes centre in Denmark.
    Safai N; Carstensen B; Vestergaard H; Ridderstråle M
    BMJ Open; 2018 Mar; 8(3):e019214. PubMed ID: 29550776
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
    Flack JM; Victor R; Watson K; Ferdinand KC; Saunders E; Tarasenko L; Jamieson MJ; Shi H; Bruschi P
    Mayo Clin Proc; 2008 Jan; 83(1):35-45. PubMed ID: 18174006
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
    Harada N; Kashiwagi A; Nishio Y; Kikkawa R
    Diabetes Res Clin Pract; 1999 Feb; 43(2):111-20. PubMed ID: 10221663
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Long-term intensive glycemic and lipid control ameliorates the carotid intima medial thickness in type 2 diabetes mellitus].
    Yang JM; Guo XH; Yu X
    Beijing Da Xue Xue Bao Yi Xue Ban; 2007 Dec; 39(6):649-52. PubMed ID: 18087561
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter PJ; Rye KA; Tardif JC; Waters DD; Boekholdt SM; Breazna A; Kastelein JJ
    Circulation; 2011 Aug; 124(5):555-62. PubMed ID: 21804130
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
    Tanaka A; Murohara T; Taguchi I; Eguchi K; Suzuki M; Kitakaze M; Sato Y; Ishizu T; Higashi Y; Yamada H; Nanasato M; Shimabukuro M; Teragawa H; Ueda S; Kodera S; Matsuhisa M; Kadokami T; Kario K; Nishio Y; Inoue T; Maemura K; Oyama J; Ohishi M; Sata M; Tomiyama H; Node K;
    Cardiovasc Diabetol; 2016 Sep; 15(1):133. PubMed ID: 27619983
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome.
    Hunninghake DB; Ballantyne CM; Maccubbin DL; Shah AK; Gumbiner B; Mitchel YB
    Clin Ther; 2003 Jun; 25(6):1670-86. PubMed ID: 12860491
    [TBL] [Abstract][Full Text] [Related]  

  • 99. LDL-cholesterol to HDL-cholesterol ratio discordance with lipid parameters and carotid intima-media thickness: a cohort study in China.
    Lou Y; Li X; Cao L; Qin P; Shi J; Zhang Y; Wang C; Ma J; Wang L; Peng X; Chen H; Xu S; Hu F; Zhao Y; Zhao P
    Lipids Health Dis; 2020 Jun; 19(1):141. PubMed ID: 32552893
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Treatment of hypercholesterolemia in NIDDM with policosanol.
    Torres O; Agramonte AJ; Illnait J; Más Ferreiro R; Fernández L; Fernández JC
    Diabetes Care; 1995 Mar; 18(3):393-7. PubMed ID: 7555484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.